Combination Phosphate Binder Therapy in CKD

Introduction to Combination Therapy

The National Kidney Foundation recommends combining sevelamer with calcium-based binders in dialysis patients with persistent hyperphosphatemia (>5.5 mg/dL) despite monotherapy, allowing for better phosphorus control while limiting the calcium load from any single agent 1, 2

Total elemental calcium intake from all sources (diet + binders + dialysate) must not exceed 2,000 mg/day, with calcium from binders alone ideally remaining under 1,500 mg/day 1, 2, 3, 4, 5
Given typical dietary calcium intake of ~500 mg/day in dialysis patients, this leaves 500-1,000 mg elemental calcium available from binders 2, 4

Before adding a second binder, calculate total elemental calcium intake, and if a patient is already receiving >2,000 mg total elemental calcium from calcium-based binders, add a non-calcium binder (like sevelamer) rather than increasing the calcium-based binder dose 2
Certain patients should have sevelamer as the dominant component of combination therapy, including those with hypercalcemia (serum calcium >10.2 mg/dL), low PTH (<150 pg/mL on two consecutive measurements), severe vascular or soft-tissue calcification, or calcium-phosphorus product >55 mg²/dL² 1, 6, 7

Monitor serum phosphorus (target 3.5-5.5 mg/dL for CKD G5D; 2.7-4.6 mg/dL for CKD G3-4), serum calcium (maintain 8.4-9.5 mg/dL), calcium-phosphorus product (maintain <55 mg²/dL²), and PTH levels to avoid oversuppression with excessive calcium 1, 3, 5

Exceeding the 2,000 mg/day total calcium threshold is associated with progressive vascular calcification, and calcium-based binders should not be used as monotherapy in patients with existing vascular calcification 2, 4, 6
Aluminum-based binders should be avoided except as short-term rescue therapy (maximum 4 weeks) for severe hyperphosphatemia (>7.0 mg/dL) 1, 5

Controlling serum phosphorus is critically important for preventing CKD-MBD complications, but this can rarely be achieved with calcium-based binders alone while staying within safe calcium limits, and the K/DOQI guidelines endorse adding non-calcium binders when calcium intake becomes excessive 2, 4
Sevelamer has the additional benefit of lowering LDL cholesterol, though whether this contributes to cardiovascular benefits remains uncertain 4, 6